A Systematic Review about the Efficacy and Safety of Tripterygium wilfordii Hook.f. Preparations Used for the Management of Rheumatoid Arthritis
Table 3
Adverse events reported.
Adverse events
TWPs
All of control group drugs
LEF
MTX
PLB
ZQFTN
DSSRC
All, (%)
264 (33.46)
137 (39.26)
2 (7.69)
100 (77.52)
3 (3.75)
4 (7.41)
28 (46.67)
Gastrointestinal, (%)
208 (26.36)
63 (18.05)
0
38 (29.46)
0
4 (7.41)
21 (35)
Blood and lymphatic system disorders, (%)
0
5 (1.43)
1 (3.85)
4 (3.10)
0
0
0
Infection, (%)
3 (0.38)
10 (2.87)
0
10 (7.75)
0
0
0
Hepatic function abnormality, (%)
10 (1.27)
16 (4.58)
1 (3.85)
12 (9.30)
1 (1.25)
0
2 (3.33)
Renal function abnormality, (%)
0
3 (0.86)
0
3 (2.33)
0
0
0
Skin and mucous event, (%)
17 (2.15)
20 (5.73)
0
14 (10.85)
2 (2.5)
0
4 (6.67)
Irregular menstruation, (%)
13 (2.07)
3 (1.08)
0
3 (2.92)
0
0
0
Headache, (%)
1 (0.13)
4 (1.15)
0
3 (2.33)
0
0
1 (1.67)
Angular cheilitis, (%)
7 (0.89)
0
0
0
0
0
Other adverse events, (%)
5 (0.63)
13 (3.72)
0
13 (10.08)
0
0
0
Note. The percentages of irregular menstruation were based on the calculated total number of female patients in each group. The calculation methods were based on female patients account for 79.65% of the total number. Other adverse events including fatigue, weight loss, anemia, palpitations, haematuria, peripheral oedema, hair loss, and unbearable smell.
